Table 2. Hazard ratios of death from bladder cancer for the FGFR4 Gly388 polymorphism and TP53 mutation status in 125 cancer patients.
| No. | Death | Death (%) | Hazard ratioa | 95% CI | P-value | |
|---|---|---|---|---|---|---|
| FGFR4 genotype | ||||||
| Gly/Gly | 59 | 38 | 64 | 1.42 | (0.83–2.40) | 0.198 |
| Arg/Arg+Arg/Gly | 66 | 34 | 52 | ref. | ||
| TP53 status | ||||||
| Abnormal | 62 | 38 | 61 | 1.53 | (0.88–2.65) | 0.133 |
| Normal | 63 | 34 | 54 | ref. | ||
| FGFR4/TP53 | ||||||
| Gly/Gly/abnormal | 28 | 21 | 75 | 2.25 | (1.04–4.88) | 0.039 |
| Gly/Gly/normal | 31 | 17 | 55 | 1.28 | (0.58–2.83) | 0.538 |
| Arg/Arg+Arg/Gly/ abnormal | 34 | 17 | 50 | 1.38 | (0.63–3.04) | 0.423 |
| Arg/Arg+Arg/Gly/ normal | 32 | 17 | 53 | ref. | ||
| Gly/Gly+abnormal | 28 | 21 | 75 | 1.85 | (1.01–3.39) | 0.046 |
| Other | 97 | 51 | 53 | ref. | ||
a
Hazard ratios were adjusted for age, gender, lymph node involvement, tumour stage and grade.